Syntimmune, Inc. Agrees to be Acquired by Alexion Pharmaceuticals, Inc. for $1.2 Billion

September 26, 2018

S&C represents Apple Tree Partners as the majority shareholder in Syntimmune, in connection with Syntimmune's definitive agreement with Alexion Pharmaceuticals, Inc., under which Alexion will acquire Syntimmune for a total value of up to $1.2 billion. The S&C team on the transaction was led by Krishna Veeraraghavan and Scott Crofton, along with Lee Parnes, Steven Mermelstein and Sammy Tang. Nader Mousavi and Mark Schenkel advised on intellectual property matters; Matthew Friestedt and Regina Readling advised on executive compensation and benefits matters; and Davis Wang and Michael Hogan advised on tax matters.